Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Etsuko Usuki, Cornelis J. Van Der Schyf & Neal Castagnoli. (1998) Metabolism of Haloperidol and Its Tetrahydropyridine Dehydration Product HPTP. Drug Metabolism Reviews 30:4, pages 809-826.
Read now
Read now
J. W. Gorrod & J. Fang. (1993) On the metabolism of haloperidol. Xenobiotica 23:5, pages 495-508.
Read now
Read now
Articles from other publishers (34)
Eric Prommer. (2011) Role of Haloperidol in Palliative Medicine. American Journal of Hospice and Palliative Medicine® 29:4, pages 295-301.
Crossref
Crossref
Yukiko Kato, Miki Nakajima, Shingo Oda, Tatsuki Fukami & Tsuyoshi Yokoi. (2012) Human UDP-Glucuronosyltransferase Isoforms Involved in Haloperidol Glucuronidation and Quantitative Estimation of Their Contribution. Drug Metabolism and Disposition 40:2, pages 240-248.
Crossref
Crossref
Tove Johansson, Lars Weidolf, Friedrich Popp, Reinhold Tacke & Ulrik Jurva. (2010) In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange. Drug Metabolism and Disposition 38:1, pages 73-83.
Crossref
Crossref
Tohru Ohnuma, Nobuto Shibata, Yoichiro Matsubara & Heii Arai. (2003) Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. British Journal of Clinical Pharmacology 56:3, pages 315-320.
Crossref
Crossref
Toshiyuki Someya, Kazutaka Shimoda, Yutaro Suzuki, Satoshi Sato, Yoshiaki Kawashima, Genta Hirokane, Sachiyo Morita, Aya Yokono & Saburo Takahashi. (2003) Effect of CYP2D6 Genotypes on the Metabolism of Haloperidol in a Japanese Psychiatric Population. Neuropsychopharmacology 28:8, pages 1501-1505.
Crossref
Crossref
Amit S. Kalgutkar, Timothy J. Taylor, Karthik Venkatakrishnan & Emre M. Isin. (2003) Assessment of the Contributions of CYP3A4 and CYP3A5 in the Metabolism of the Antipsychotic Agent Haloperidol to Its Potentially Neurotoxic Pyridinium Metabolite and Effect of Antidepressants on the Bioactivation Pathway. Drug Metabolism and Disposition 31:3, pages 243-249.
Crossref
Crossref
Donald J. AbrahamC. Anthony Altar, Arnold R. Martin & Andrew Thurkauf. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
599
672
.
Kazutaka Shimoda, Toshiyuki Someya, Sachiyo Morita, Genta Hirokane, Aya Yokono, Saburo Takahashi & Masako Okawa. (2002) Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position −2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26:2, pages 261-265.
Crossref
Crossref
Hyung-Keun Roh, Jea-Yon Chung, Dong-Yul Oh, Chang-Shin Park, Jan-Olof Svensson, Marja-Liisa Dahl & Leif Bertilsson. (2001)
Plasma concentrations of haloperidol are related to
CYP2D6
genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
. British Journal of Clinical Pharmacology 52:3, pages 265-271.
Crossref
Crossref
Yutaro Suzuki, Toshiyuki Someya, Kazutaka Shimoda, Genta Hirokane, Sachiyo Morita, Aya Yokono, Yoshimasa Inoue & Saburo Takahashi. (2001) Importance of the Cytochrome P450 2D6 Genotype for the Drug Metabolic Interaction Between Chlorpromazine and Haloperidol. Therapeutic Drug Monitoring 23:4, pages 363-368.
Crossref
Crossref
Rimmel Fukuda. (2000) Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring. Progress in Neuro-Psychopharmacology and Biological Psychiatry 24:8, pages 1299-1318.
Crossref
Crossref
Kazutaka Shimoda, Sachiyo Morita, Aya Yokono, Toshiyuki Someya, Genta Hirokane, Noriyuki Sunahara & Saburo Takahashi. (2000) CYP2D6*10 Alleles Are Not the Determinant of the Plasma Haloperidol Concentrations in Asian Patients. Therapeutic Drug Monitoring 22:4, pages 392-396.
Crossref
Crossref
Liping Pan, Robert Vander Stichele, Marie T. Rosseel, Jacques A. Berlo, Nadine De Schepper & Frans M. Belpaire. (1999) Effects of Smoking, CYP2D6 Genotype, and Concomitant Drug Intake on the Steady State Plasma Concentrations of Haloperidol and Reduced Haloperidol in Schizophrenic Inpatients. Therapeutic Drug Monitoring 21:5, pages 489.
Crossref
Crossref
Toshiyuki Someya, Yutaro Suzuki, Kazutaka Shimoda, Genta Hirokane, Sachiyo Morita, Aya Yokono, Yoshimasa Inoue & Saburo Takahashi. (2002) The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population. Psychiatry and Clinical Neurosciences 53:5, pages 593-597.
Crossref
Crossref
Kazutaka Shimoda, Toshiyuki Someya, Sachiyo Morita, Genta Hirokane, Toshifumi Noguchi, Aya Yokono, Morikazu Shibasaki & Saburo Takahashi. (1999) Lower Plasma Levels of Haloperidol in Smoking Than in Nonsmoking Schizophrenic Patients. Therapeutic Drug Monitoring 21:3, pages 293.
Crossref
Crossref
Minoru Watanabe, Tomonori Tateishi, Masako Asoh, Hironori Nakura, Masami Tanaka, Toshio Kumai & Shinichi Kobayashi. (2009) Role of CYP3A in haloperidol N‐dealkylation and pharmacokinetics in rats. Fundamental & Clinical Pharmacology 13:3, pages 337-342.
Crossref
Crossref
Genta Hirokane, Toshiyuki Someya, Saburo Takahashi, Sachiyo Morita & Kazutaka Shimoda. (1999) Interindividual Variation of Plasma Haloperidol Concentrations and the Impact of Concomitant Medications: The Analysis of Therapeutic Drug Monitoring Data. Therapeutic Drug Monitoring 21:1, pages 82-86.
Crossref
Crossref
Norio Yasui, Koichi Otani, Tsuyoshi Kondo, Akihito Suzuki, hanako Furukori, Sunao Kaneko & Yoshimasa Inoue. (1998) Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 22:3, pages 485-492.
Crossref
Crossref
D. W. Eyles, J. J. McGrath & S. M. Pond. (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 125:3, pages 214-219.
Crossref
Crossref
J. Fang & P. H. Yu. (1995) Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology 121:3, pages 379-384.
Crossref
Crossref
J. Fang, P. H. Yu, A. A. Boulton & J. W. Gorrod. (1995) Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology 118:2, pages 206-212.
Crossref
Crossref
Darryl W. Eyles, Terry J. Stedman & Susan M. Pond. (1994) Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 116:2, pages 161-166.
Crossref
Crossref
Michael W. Jann, Y.W. Francis Lam, Eric C. Gray & Wen-Ho Chang. (1994) REVERSIBLE METABOLISM OF DRUGS. Drug Metabolism and Drug Interactions 11:1, pages 1-24.
Crossref
Crossref
G. D. Nordblom & C. M. Barksdale. 1994. Pharmacokinetics of Drugs. Pharmacokinetics of Drugs
23
39
.
Seth Y. Ablordeppey & Ronald F. Borne. (1993) Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Pharmacology Biochemistry and Behavior 46:3, pages 739-744.
Crossref
Crossref
D. Young, K. K. Midha, M. J. Fossler, E. M. Hawes, J. W. Hubbard, G. McKay & E. D. Korchinski. (1993) Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. European Journal of Clinical Pharmacology 44:5, pages 433-438.
Crossref
Crossref
Jian Fang & John W. Gorrod. (1993) High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. Journal of Chromatography B: Biomedical Sciences and Applications 614:2, pages 267-273.
Crossref
Crossref
Shibasaki Morikazu, Someya Toshiyuki & Takahashi Saburo. (1993) Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population. Progress in Neuro-Psychopharmacology and Biological Psychiatry 17:2, pages 257-267.
Crossref
Crossref
Shih-Ku Lin, Wen-Ho Chang, Y. W. Francis Lam & Michael W. Jann. (2012) Variability in Declining Haloperidol and Reduced Haloperidol Plasma Concentrations upon Haloperidol Cessation. Drug Investigation 5:1, pages 57-62.
Crossref
Crossref
Jian Fang, John W. Gorrod, Mahmud Kajbaf, John H. Lamb & Stephen Naylor. (1992) Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometry. International Journal of Mass Spectrometry and Ion Processes 122, pages 121-131.
Crossref
Crossref
Seth Y. Ablordeppey, Ronald F. Borne & W.Marvin Davis. (1992) Freezing action of a metabolite of haloperidol in frogs. Biochemical Pharmacology 43:10, pages 2181-2187.
Crossref
Crossref
Wen-Ho Chang. (1992) Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?. Psychopharmacology 106:3, pages 289-296.
Crossref
Crossref
Yoshiaki Terauchi, Shoko Ishikawa, Sachiko Oida, Masashi Nakao, Akira Kagemoto, Tetsuya Oida, Yuzo Utsui & Yutaka Sekine. (1990) Direct Radioimmunoassay for Haloperidol in Human Serum. Journal of Pharmaceutical Sciences 79:5, pages 432-436.
Crossref
Crossref
Babu Subramanyam, Hans Rollema, Thomas Woolf & Neal CastagnoliJr.Jr.. (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochemical and Biophysical Research Communications 166:1, pages 238-244.
Crossref
Crossref